The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women

Abstract

At a time when the prevalence of osteoporosis and related fractures is increasing, initiation and continuation of pharmacologic therapies for prevention and treatment of postmenopausal osteoporosis have declined. This decline has been at least in part attributable to concerns about safety of these agents, such as atypical fractures with bisphosphonates and breast cancer with estrogen/progestin therapy, particularly when they are used long term by older women. However, in many cases, absolute risk of serious adverse effects is small and should be balanced against the larger potential for fracture reduction. Here, we review the safety and tolerability of available therapies for postmenopausal osteoporosis. Taking into consideration their relative efficacy, we also provide strategies for optimization of the risk:benefit ratio.

Keywords: SERMs; bisphosphonates; calcitonin; conjugated estrogens/bazedoxifene; denosumab; hormone therapy; postmenopausal osteoporosis; safety; strontium ranelate; teriparatide.